Tackling the tumor microenvironment: what challenge does it pose to anticancer therapies?

Abstract

Cancer is a highly aggressive and devastating disease, and impediments to a cure arise not just from cancer itself. Targeted therapies are difficult to achieve since the majority of cancers are more intricate than ever imagined. Mainstream methodologies including chemotherapy and radiotherapy as routine clinical regimens frequently fail, eventually leading to pathologies that are refractory and incurable. One major cause is the gradual to rapid repopulation of surviving cancer cells during intervals of multiple-dose administration. Novel stress-responsive molecular pathways are increasingly unmasked and show promise as emerging targets for advanced strategies that aim at both de novo and acquired resistance. We highlight recent data reporting that treatments particularly those genotoxic can induce highly conserved damage responses in non-cancerous constituents of the tumor microenvironment (TMEN). Master regulators, including but not limited to NF-kB and C/EBP-β, are implicated and their signal cascades culminate in a robust, chronic and genome-wide secretory program, forming an activated TMEN that releases a myriad of soluble factors. The damage-elicited but essentially off target and cell non-autonomous secretory phenotype of host stroma causes adverse consequences, among which is acquired resistance of cancer cells. Harnessing signals arising from the TMEN, a pathophysiological niche frequently damaged by medical interventions, has the potential to promote overall efficacy and improve clinical outcomes provided that appropriate actions are ingeniously integrated into contemporary therapies. Thereby, anticancer regimens should be well tuned to establish an innovative clinical avenue, and such advancement will allow future oncological treatments to be more specific, accurate, thorough and personalized.

Keywords

tumor microenvironment / DNA damage / secretory phenotype / therapy resistance / genotoxicity / clinical intervention

References

[1] Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, Fumagalli M, Da Costa M, Brown C, Popov N, Takatsu Y, Melamed J, d'Adda di Fagagna F, Bernard D, Hernando E, Gil J (2008) Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell133: 1006-1018

[2] Alspach E, Flanagan KC, Luo X, Ruhland MK, Huang H, Pazolli E, Donlin MJ, Marsh T, Piwnica-Worms D, Monahan J, Novack DV, McAllister SS, Stewart SA (2014) p38MAPK plays a crucial role in stromal-mediated tumorigenesis. Cancer Discov4: 716-729

[3] Bhaumik D, Scott GK, Schokrpur S, Patil CK, Orjalo AV, Rodier F, Lithgow GJ, Campisi J (2009) MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging (Albany NY)1: 402-411

[4] Blasi F, Carmeliet P (2002) uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol3: 932-943

[5] Borodkina A, Shatrova A, Abushik P, Nikolsky N, Burova E (2014) Interaction between ROS dependent DNA damage, mitochondria and p38 MAPK underlies senescence of human adult stem cells. Aging (Albany NY)6: 481-495

[6] Bourzac K (2014) Biology: three known unknowns. Nature509: S69-S71

[7] Campisi J (2013) Aging, cellular senescence, and cancer. Annu Rev Physiol75: 685-705

[8] Campisi J (2014) Cell biology: the beginning of the end. Nature505: 35-36

[9] Chandler H, Peters G (2013) Stressing the cell cycle in senescence and aging. Curr Opin Cell Biol6: 765-771

[10] Chien Y, Scuoppo C, Wang X, Fang X, Balgley B, Bolden JE, Premsrirut P, Luo W, Chicas A, Lee CS, Kogan SC, Lowe SW (2011) Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev25: 2125-2136

[11] Collado M, Serrano M (2010) Senescence in tumours: evidence from mice and humans. Nat Rev Cancer10: 51-57

[12] Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J (2008) Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol6: 2853-2868

[13] Coppe JP, Desprez PY, Krtolica A, Campisi J (2010) The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol5: 99-118

[14] Coppé J-P, Rodier F, Patil CK, Freund A, Desprez PY, Campisi J (2011) Tumor suppressor and aging biomarker p16INK4a induces cellular senescence without the associated inflammatory secretory phenotype. J Biol Chem286: 36396-36403

[15] Costantino L, Sotiriou SK, Rantala JK, Magin S, Mladenov E, Helleday T, Haber JE, Iliakis G, Kallioniemi OP, Halazonetis TD (2014) Break-induced replication repair of damaged forks induces genomic duplications in human cells. Science343: 88-91

[16] Coussens LM, Zitvogel L, Palucka AK (2013) Neutralizing tumorpromoting chronic inflammation: a magic bullet? Science339: 286-291

[17] d'Adda di Fagagna F (2008) Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer8: 512-522

[18] Davalos AR, Coppe JP, Campisi J, Desprez PY (2010) Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev29: 273-283

[19] de Bono JS, Sandhu S, Attard G (2011) Beyond hormone therapy for prostate cancer with PARP inhibitors. Cancer Cell19: 573-574

[20] Freund A, Orjalo AV, Desprez PY, Campisi J (2010) Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med16: 238-246

[21] Freund A, Patil PK, Campisi J (2011) p38MAPK is a novel DNA damage response-independent regulator of the senescenceassociated secretory phenotype. EMBO J30: 1536-1548

[22] Fumagalli M, d’Adda di Fagagna F (2009) SASPense and DDRama in cancer and ageing. Nat Cell Biol11: 921-923

[23] Garber K (2013) PARP inhibitors bounce back. Nat Rev Drug Discov12: 725-727

[24] Gilbert LA, Hemann MT (2010) DNA damage-mediated induction of a chemoresistant niche. Cell143: 355-366

[25] Gilbert LA, Hemann MT (2011) Chemotherapeutic resistance: surviving stressful situations. Cancer Res71: 5062-5066

[26] Goruppi S, Dotto GP (2013) Mesenchymal stroma: primary determinant and therapeutic target for epithelial cancer. Trends Cell Biol23: 593-602

[27] Gupta SC, Sung B, Prasad S, Webb LJ, Aggarwal BB (2013) Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci34: 508-517

[28] Hallek M, Chen J, Hemann MT (2014) Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell156: 590-602

[29] Harrison C (2013) Pharmacokinetics: single-cell imaging adds insight into drug action. Nat Rev Drug Discov12: 264

[30] Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer8: 193-204

[31] Helleday T, Eshtad S, Nik-Zainal S (2014) Mechanisms underlying mutational signatures in human cancers. Nat Rev Genet15: 585-598

[32] Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature461: 1071-1078

[33] Junttila MR, de Sauvage FJ (2013) Influence of tumour microenvironment heterogeneity on therapeutic response. Nature501: 346-354

[34] Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell141: 52-67

[35] Kim JJ, Tannock IF (2005) Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer5: 516-525

[36] Köpper F, Bierwirth C, Schön M, Kunze M, Elvers I, Kranz D, Saini P, Menon MB, Walter D, Sørensen CS, Gaestel M, Helleday T, Schön MP, Dobbelstein M (2013) Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity. Proc Natl Acad Sci USA110: 16856-16861

[37] Kuilman T, Peeper DS (2009) Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer9: 81-94

[38] Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS (2008) Oncogeneinduced senescence relayed by an interleukin-dependent inflammatory network. Cell133: 1019-1031

[39] Liu D, Hornsby PJ (2007) Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res67: 3117-3126

[40] Moiseeva O, Deschênes-Simard X, St-Germain E, Igelmann S, Huot G, Cadar AE, Bourdeau V, Pollak MN, Ferbeyre G (2013) Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation. Aging Cell12: 489-498

[41] Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer9: 274-284

[42] Norton L, Simon R (1986) The Norton-Simon hypothesis revisited. Cancer Treat Rep70: 163-169

[43] Ohanna M, Giuliano S, Bonet C, Imbert V, Hofman V, Zangari L, Bille K, Robert C, Bressac-de Paillerets B, Hofman P, Rocchi S, Peyron JF, Lacour JP, Ballotti R, Bertolotto C (2011) Senescent cells develop a PARP-1 and nuclear factor-êB-associated secretome (PNAS). Genes Dev25: 1245-1261

[44] Orjalo A, BhaumikD Gengler B, ScottGK Campisi J (2009) Cell surface IL-1α is an upstream regulator of the senescenceassociated IL-6/IL-8 cytokine network. Proc Natl Acad Sci USA106: 17031-17036

[45] Ozdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R (2014) Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell25: 719-734

[46] Pallasch CP, Leskov I, Braun CJ, Vorholt D, Drake A, Soto-Feliciano YM, Bent EH, Schwamb J, Iliopoulou B, Kutsch N, van Rooijen N, Frenzel LP, Wendtner CM, Heukamp L, Kreuzer KA, Palucka K, Banchereau J (2014) SnapShot: cancer vaccines. Cell157: 516

[47] Palucka K, Banchereau J (2014) SnapShot: cancer vaccines. Cell157: 516-516

[48] Patel KJ, Lee C, Tan Q, Tannock IF (2013) Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clin Cancer Res19: 6766-6776

[49] Pulukuri SMK, Knost JA, Estes N, Rao JS (2009) Small interfering RNA-directed knockdown of uracil DNA glycosylase induces apoptosis and sensitizes human prostate cancer cells to genotoxic stress. Mol Cancer Res7: 1285-1293

[50] Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, Fernandez-Zapico ME, Iacobuzio-Donahue C, Olive KP, Stanger BZ (2014) Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell25: 735-747

[51] Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, Freund A, Campeau E, Davalos AR, Campisi J (2009) Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol.11: 973-979

[52] Rodier F, Munoz DP, Teachenor R, Chu V, Le O, Bhaumik D, Coppé JP, Campeau E, Beauséjour CM, Kim SH, Davalos AR, Campisi J (2011) DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J Cell Sci124: 68-81

[53] Sale JE, Lehmann AR, Woodgate R (2012) Y-family DNA polymerases and their role in tolerance of cellular DNA damage. Nat Rev Mol Cell Biol13: 141-152

[54] Schmitt CA (2003) Senescence, apoptosis and therapy—cutting the lifelines of cancer. Nat Rev Cancer3: 286-295

[55] Sun Y, Nelson PS (2012) Molecular pathways: involving microenvironment damage responses in cancer therapy resistance. Clin Cancer Res 18: 4019-4025

[56] Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS (2012) Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med18: 1359-1368

[57] Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006) NF-kBdependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. PNAS103: 12481-12486

[58] Tell G, Wilson DM III (2010) Targeting DNA repair proteins for cancer treatment. Cell Mol Life Sci67: 3569-3572

[59] Tentori L, Muzi A, Dorio AS, Scarsella M, Leonetti C, Shah GM, Xu W, Camaioni E, Gold B, Pellicciari R, Dantzer F, Zhang J, Graziani G (2010) Pharmacological inhibition of poly(ADPribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent. Curr Cancer Drug Targets 10: 368-383

[60] Tomé M, Sepúlveda JC, Delgado M, Andrades JA, Campisi J, González MA, Bernad A (2014) MiR-335 correlates with senescence/aging in human mesenchymal stem cells and inhibits their therapeutic actions through inhibition of AP-1 activity. Stem Cells32: 2299-2344

[61] Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer8: 755-768

[62] Wang Z, Chen W (2013) Emerging roles of SIRT1 in cancer drug resistance. Genes Cancer4: 82-90

[63] Yu M, Tannock IF (2012) Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer? Cancer Cell21: 327-329

[64] Yu M, Ocana A, Tannock IF (2013) Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Metastasis Rev32: 211-227

RIGHTS & PERMISSIONS

2014 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.